Clinical Trial Update: Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate the efficacy and safety of SPA100, a fixed-dose combination of aliskiren and amlodipine, in adults with essential hypertension. R…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• SPA100 (aliskiren/amlodipine)

Snippet

Sponsor: Novartis | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2012-06-13